# A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

> **NCT02859207** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 32 (actual)

## Conditions studied

- Early Alzheimer's Disease

## Interventions

- **DRUG:** E2609

## Key facts

- **NCT ID:** NCT02859207
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2016-12-06
- **Final completion:** 2017-01-25
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859207, "A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02859207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*